From GlobeNewswire: 2024-05-08 01:00:00

Pharming Group N.V. reported a 31% increase in first quarter 2024 revenues to US$55.6 million, driven by the U.S. commercial launch of Joenja® and revenue growth of RUCONEST®. RUCONEST® revenues increased by 8% to US$46.0 million, while Joenja® revenue rose to US$9.6 million, on track to meet 2024 total revenue guidance of US$280 million – US$295 million.

The company has strong cash and marketable securities of US$203.5 million at the end of the quarter. Pharming is hosting a conference call to discuss their preliminary financial report for the three months ended March 31, 2024. Pharming CEO, Sijmen de Vries, highlighted strong revenue growth driven by Joenja® and RUCONEST®, with additional patients enrolled and pending in their access programs.

Pharming’s RUCONEST® saw a revenue increase of 8% to US$46.0 million in the first quarter of 2024. The U.S. market accounted for 97% of revenues, with almost 70 new patients enrolled during the quarter. Joenja® revenue increased to US$9.6 million, driven by patient growth in the U.S. and revenues from EU and Rest of World. Pharming identified over 840 diagnosed APDS patients globally.

Pharming continues to advance initiatives to diagnose additional APDS patients through genetic testing programs and family testing. They are working on VUS resolution efforts to confirm genetic variants causing APDS. Pharming made progress in the first quarter of 2024 on leniolisib regulatory filings for APDS patients, with ongoing clinical trials to support regulatory filings in Japan and pediatric label expansion. They are working to make leniolisib commercially available in key markets.



Read more at GlobeNewswire:: Pharming Group reports first quarter 2024 financial